Dr Dominik Froehlich
Lecturer

Dr Dominik Froehlich

  • PhD (2014 - Summa cum laude; Johannes Gutenberg University Mainz). Thesis: Oligodendroglial Exosomes in Glia to Neuron Signaling
  • MSc (2009 - with distinction; Johannes Gutenberg University Mainz)

Medicine & Health
School of Medical Sciences

I am a neuroscientist with a broad background in genetics, neuroscience, and molecular cell biology. My research seeks to establish innovative new gene therapies for the group of devastating neurodegenerative disorders termed leukodystrophies - genetic diseases of the central nervous system white matter associated with an early onset, substantial mortality, and a lack of effective treatment options. My research has significantly advanced the understanding of these diseases and successfully utilised refined CNS-targeted gene therapy to rescue disease pathology in mice. I have over 13 years of experience in translational neuroscience including in vivo disease modelling and the development of targeted gene therapies.

At UNSW Sydney, I co-lead the CNS Gene Therapy group within the Translational Neuroscience Facility. I am a committee member of the UNSW Animal Care and Ethics Committee and engage with the non-scientific community through my work for two not-for-profit organisations. I am the Vice President and Scientific Advisor of Leukodystrophy Australia, an organisation that provides information, support, and advocacy to those affected by leukodystrophies. I am also Scientific Advisory Board Member to the Mission Massimo Foundation, aimed at accelerating the discovery of genetic variations responsible for childhood leukodystrophies and to translate these findings into clinical treatments.

  • Journal articles | 2022
    Fröhlich D; Gessler DJ; Klugmann M, 2022, 'Editorial: Myelin Repair: At the Crossing-Lines of Myelin Biology and Gene Therapy', Frontiers in Cellular Neuroscience, vol. 16, http://dx.doi.org/10.3389/fncel.2022.853742
    Journal articles | 2022
    Klugmann M; Kalotay E; Delerue F; Ittner LM; Bongers A; Yu J; Morris MJ; Housley GD; Fröhlich D, 2022, 'Correction to: Developmental delay and late onset HBSL pathology in hypomorphic Dars1 M256L mice (Neurochemical Research, (2022), 47, 7, (1972-1984), 10.1007/s11064-022-03582-4)', Neurochemical Research, vol. 47, pp. 1985 - 1990, http://dx.doi.org/10.1007/s11064-022-03602-3
    Journal articles | 2022
    Klugmann M; Kalotay E; Delerue F; Ittner LM; Bongers A; Yu J; Morris MJ; Housley GD; Fröhlich D, 2022, 'Developmental delay and late onset HBSL pathology in hypomorphic Dars1 M256L mice', Neurochemical Research, vol. 47, pp. 1972 - 1984, http://dx.doi.org/10.1007/s11064-022-03582-4
    Journal articles | 2021
    Fröhlich D; Mendes MI; Kueh AJ; Bongers A; Herold MJ; Salomons GS; Housley GD; Klugmann M, 2021, 'A Hypomorphic Dars1D367Y Model Recapitulates Key Aspects of the Leukodystrophy HBSL', Frontiers in Cellular Neuroscience, vol. 14, pp. 625879, http://dx.doi.org/10.3389/fncel.2020.625879
    Journal articles | 2021
    Muthiah A; Housley GD; Klugmann M; Fröhlich D, 2021, 'The Leukodystrophies HBSL and LBSL—Correlates and Distinctions', Frontiers in Cellular Neuroscience, vol. 14, http://dx.doi.org/10.3389/fncel.2020.626610
    Journal articles | 2020
    Das A; Fröhlich D; Achanta LB; Rowlands BD; Housley GD; Klugmann M; Rae CD, 2020, 'Correction to: L-Aspartate, L-Ornithine and L-Ornithine-L-Aspartate (LOLA) and Their Impact on Brain Energy Metabolism (Neurochemical Research, (2020), 45, 6, (1438-1450), 10.1007/s11064-020-03044-9)', Neurochemical Research, vol. 45, pp. 2527, http://dx.doi.org/10.1007/s11064-020-03087-y
    Journal articles | 2020
    Das A; Fröhlich D; Achanta LB; Rowlands BD; Housley GD; Klugmann M; Rae CD, 2020, 'L-Aspartate, L-Ornithine and L-Ornithine-L-Aspartate (LOLA) and Their Impact on Brain Energy Metabolism', Neurochemical Research, vol. 45, pp. 1438 - 1450, http://dx.doi.org/10.1007/s11064-020-03044-9
    Journal articles | 2020
    Frühbeis C; Kuo-Elsner WP; Müller C; Barth K; Peris L; Tenzer S; Möbius W; Werner HB; Nave KA; Fröhlich D; Krämer-Albers EM, 2020, 'Oligodendrocytes support axonal transport and maintenance via exosome secretion', PLoS Biology, vol. 18, pp. e3000621, http://dx.doi.org/10.1371/journal.pbio.3000621
    Journal articles | 2019
    Auber M; Fröhlich D; Drechsel O; Karaulanov E; Krämer-Albers EM, 2019, 'Serum-free media supplements carry miRNAs that co-purify with extracellular vesicles', Journal of Extracellular Vesicles, vol. 8, pp. 1656042 - 1656042, http://dx.doi.org/10.1080/20013078.2019.1656042
    Journal articles | 2018
    Fröhlich D; Suchowerska AK; Voss C; He R; Wolvetang E; Von Jonquieres G; Simons C; Fath T; Housley GD; Klugmann M, 2018, 'Expression pattern of the aspartyl-tRNA synthetase DARS in the human brain', Frontiers in Molecular Neuroscience, vol. 11, http://dx.doi.org/10.3389/fnmol.2018.00081
    Journal articles | 2018
    von Jonquieres G; Spencer ZHT; Rowlands BD; Klugmann CB; Bongers A; Harasta AE; Parley KE; Cederholm J; Teahan O; Pickford R; Delerue F; Ittner LM; Fröhlich D; McLean CA; Don AS; Schneider M; Housley GD; Rae CD; Klugmann M, 2018, 'Uncoupling N-acetylaspartate from brain pathology: implications for Canavan disease gene therapy', Acta Neuropathologica, vol. 135, pp. 95 - 113, http://dx.doi.org/10.1007/s00401-017-1784-9
    Journal articles | 2017
    Fröhlich D; Suchowerska AK; Spencer ZHT; von Jonquieres G; Klugmann CB; Bongers A; Delerue F; Stefen H; Ittner LM; Fath T; Housley GD; Klugmann M, 2017, 'In vivo characterization of the aspartyl-tRNA synthetase DARS: Homing in on the leukodystrophy HBSL', Neurobiology of Disease, vol. 97, pp. 24 - 35, http://dx.doi.org/10.1016/j.nbd.2016.10.008
    Journal articles | 2016
    von Jonquieres G; Fröhlich D; Klugmann CB; Wen X; Harasta AE; Ramkumar R; Spencer ZHT; Housley GD; Klugmann M, 2016, 'Recombinant human myelin-associated glycoprotein promoter drives selective AAV-mediated transgene expression in oligodendrocytes', Frontiers in Molecular Neuroscience, vol. 9, http://dx.doi.org/10.3389/fnmol.2016.00013
    Journal articles | 2014
    Froehlich D; Fruehbeis C; Kuo WP; Moebius W; Goebbels S; Nave K-A; Schneider A; Simons M; Klugmann M; Trotter J; Kraemer-Albers E-M, 2014, 'Transfer of exosomes from oligodendrocytes to neurons', ACTA PHYSIOLOGICA, vol. 210, pp. 134 - 134, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000332259900346&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
    Journal articles | 2014
    Fröhlich D; Kuo WP; Frühbeis C; Sun JJ; Zehendner CM; Luhmann HJ; Pinto S; Toedling J; Trotter J; Krämer-Albers EM, 2014, 'Multifaceted effects of oligodendroglial exosomes on neurons: Impact on neuronal firing rate, signal transduction and gene regulation', Philosophical Transactions of the Royal Society B: Biological Sciences, vol. 369, http://dx.doi.org/10.1098/rstb.2013.0510
    Journal articles | 2013
    Frühbeis C; Fröhlich D; Kuo WP; Amphornrat J; Thilemann S; Saab AS; Kirchhoff F; Möbius W; Goebbels S; Nave KA; Schneider A; Simons M; Klugmann M; Trotter J; Krämer-Albers EM, 2013, 'Neurotransmitter-Triggered Transfer of Exosomes Mediates Oligodendrocyte-Neuron Communication', PLoS Biology, vol. 11, http://dx.doi.org/10.1371/journal.pbio.1001604
    Journal articles | 2013
    Frühbeis C; Fröhlich D; Kuo WP; Krämer-Albers EM, 2013, 'Extracellular vesicles as mediators of neuron-glia communication', Frontiers in Cellular Neuroscience, http://dx.doi.org/10.3389/fncel.2013.00182
    Journal articles | 2013
    Von Jonquieres G; Mersmann N; Klugmann CB; Harasta AE; Lutz B; Teahan O; Housley GD; Frohlich D; Kramer-Albers EM; Klugmann M, 2013, 'Glial Promoter Selectivity following AAV-Delivery to the Immature Brain', PLoS ONE, vol. 8, pp. Article number e65646, http://dx.doi.org/10.1371/journal.pone.0065646
    Journal articles | 2012
    Frühbeis C; Fröhlich D; Krämer-Albers EM, 2012, 'Emerging roles of exosomes in neuron-glia communication', Frontiers in Physiology, vol. 3 APR, http://dx.doi.org/10.3389/fphys.2012.00119
  • Conference Abstracts | 2017
    von Jonquieres G; Klugmann C; Frohlich D; Housley GD; Klugmann M, 2017, 'NOVEL APPROACHES TO PREVENT THE NAASTY - TARGETED GENE THERAPY FOR LEUKODYSTROPHIES', in JOURNAL OF GENE MEDICINE, WILEY, Univ Technol Sydney, Sydney, AUSTRALIA, Vol. 20, presented at Joint 10th Annual Scientific Meeting of the Australian-Gene-and-Cell-Therapy-Society (AGCTS) and Australasian-Society-for-Stem-Cell-Research (ASSCR), Univ Technol Sydney, Sydney, AUSTRALIA, 24 May 2017 - 26 May 2017, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000426528300030&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

  • National Health and Medical Research Council (NHMRC) Ideas Grant (2021 - 2026); Bionic-array Directed Gene Electrotransfer for Treating Focal Brain Disorders ($1,941,000)
  • Medical Research Future Fund (MRFF) Accelerated Research (2019 -2023)Massimo’s Mission – The Leukodystrophy Flagship ($3,000,000)
  • European Leukodystrophy Association (ELA)project grant (2019 -2022); Towards preclinical proof-of-concept for HBSL gene therapy ($316,000)
  • European Leukodystrophy Association (ELA) pilot grant (2016); Modelling and treatment of the novel leukoencephalopathy HBSL ($69,000)
  • German Research Foundation DFG - Early Career Research Fellowship (2014 -2016)Exosome-mediated nanomedicine for the treatment of leukodystrophies ($126,000)

  • UNSW Sydney SoMS New Researcher of the Year (2019)                                                                                                                               
  • UNSW Sydney SoMS Paper of the Month award (2018)     

I have established a comprehensive research program focused on developing innovative new gene therapy strategies for a group of devastating neurodegenerative disorders termed leukodystrophies. My research program can be split into two main activities:

  • Creation and characterisation of novel disease models, which are integral in understanding the underlying pathophysiology of leukodystrophies 
  • Pre-clinical efficacy studies demonstrating the effectiveness of AAV-mediated gene therapy for the treatment of leukodystrophies and other brain disorders

Professional Engagement

  • UNSW Animal Care and Ethics Committee Member (since 2021)
  • Rare Disease and Orphan Drugs Journal (RDODJ) - Editorial Board Member (since 2021)                                                                                                               
  • Frontiers in Cellular Neuroscience - Guest Editor (2020); Topic: Myelin Repair: At the Crossing-Lines of Myelin Biology and Gene Therapy                                                                                                           

Social Engagement

  • Leukodystrophy Australia Foundation - Vice President and Scientific Advisor (since 2019)                                                                                                                                         
  • Mission Massimo Foundation – Scientific Advisor (since 2014)                                                                                                                                                       

Media

  • ABC Australian Story (2018) The Massimo Mission. https://www.abc.net.au/austory/the-massimo-mission/9771118                                                                                                                                                            

I contribute to teaching and student supervision into Science and Medicine courses, including lecturing Current Trends in Biotechnology, facilitating in the phase 1 medicine program, tutoring, and demonstrating.